Effectiveness of Dynamiclear published in the Journal of Drugs in Dermatology

The Dynamiclear Phase III Clinical Trial was peer-reviewed by an independent panel of experts^[1] and the findings have now been published in the prestigious
Journal of Drugs in Dermatology (New York), February 2012, Issue 11, Volume 2.



This publication demonstrates the promising potential of Dynamiclear as a single application treatment for relief of Herpes Simplex virus (HSV-1 and HSV-2) symptoms.

Dynamiclear was shown to be at least equally as effective as the comparator product Acyclovir, with the added benefit of only requiring a SINGLE APPLICATION – ONCE.

Not multiple applications for multiple days.

Access the full Clinical Trial publication at these links.

• Dynamiclear Clinical Trial published in the Journal of Drugs and Dermatology
  
• PubMed listing of the Dynamiclear Clinical Trial
  

Overview of the JDD publication:

Title: Efficacy and Tolerability Assessment of a Topical Formulation Containing Copper Sulfate and Hypericum perforatum on Patients With Herpes Skin Lesions: A Comparative, Randomized Controlled Trial

Background: Topical Acyclovir has moderate efficacy on recurrent HSV symptoms, requiring repeat applications for several days. Topical Dynamiclear, which requires only a single dose application, may provide a more effective and convenient treatment option for symptomatic management of HSV.

Objectives: The study assessed the comparative efficacy and tolerability of a single use, topical formulation containing copper sulfate pentahydrate and Hypericum perforatum that is marketed as Dynamiclear™ to a topical 5% Acyclovir cream standard preparation and use.

Methods: A prospective, randomized, multi-centered, comparative, open-label clinical study was conducted. A total of 149 participants between 18 and 55 years of age with active HSV-1 and HSV-2 lesions were recruited for the 14-day clinical trial. Participants were randomized into two groups: A (n=61), those receiving the Dynamiclear formulation, and B (n=59), those receiving 5% Acyclovir. Efficacy parameters were assessed via physical examination at baseline (day 1), day 2, 3, 8, and 14. Laboratory safety tests were conducted at baseline and on day 14.

Results: Use of the Dynamiclear formulation was found to have no significant adverse effects and was well tolerated by participants. All hematological and biochemical markers were within normal range for the Dynamiclear group. Statistically, odds for being affected by burning and stinging sensation were 1.9 times greater in the Acyclovir group in comparison to the Dynamiclear group. Similarly, the odds of being affected by symptoms of acute pain, erythema and vesiculation were 1.8, 2.4, and 4.4 times higher in the Acyclovir group in comparison to the Dynamiclear group.

Conclusions: The Dynamiclear formulation was well tolerated, and efficacy was demonstrated in a number of measured parameters, which are helpful in the symptomatic management of HSV-1 and HSV-2 lesions in adult patients. Remarkably, the effects seen from this product came from a single application.

1. The Dynamiclear Phase III clinical trial has been peer-reviewed by Amy Clewell ND, Matt Barnes MS, John R. Endres ND, Mansoor Ahmed PhD and Daljit K. S. Ghambeer MD.

Find out more information on how Dynamiclear can help you.